Inactive Instrument

Analyst Reco. EntreMed Inc Nasdaq

Equities

US29382F2020

End-of-day quote Nasdaq Other stock markets
- ^USD	-

Jul. 08	CASI Pharmaceuticals Names Daniel Lang CFO	MT
Jul. 08	CASI Pharmaceuticals, Inc. Appoints Daniel Lang as CFO	CI

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

HC Wainwright Raises Price Target on CASI Pharmaceuticals to $12 From $10, Keeps Buy Rating	Nov. 15	MT
BTIG Adjusts CASI Pharmaceuticals' Price Target to $10 From $21, Keeps Buy Rating	22-11-16	MT
CORRECTION : BTIG Lowers CASI Pharmaceuticals' Price Target to $21 From $40, Buy Rating Kept	22-08-15	MT
HC Wainwright Lowers CASI Pharmaceuticals' Price Target to $12 From $30, Buy Rating Maintained	22-08-15	MT
Oppenheimer Adjusts CASI Pharmaceuticals' Price Target to $35 From $6 After Reverse Stock Split, Maintains Outperform Rating	22-08-15	MT
BTIG Raises CASI Pharmaceuticals' Price Target to $21 From $40, Buy Rating Kept	22-06-03	MT
HC Wainwright Adjusts CASI Pharmaceuticals' Price Target to $3 from $4, Keeps Buy Rating	22-05-16	MT
CASI PHARMACEUTICALS : BTIG Initiates CASI Pharmaceuticals at Buy Rating With $4 Price Target	21-05-18	MT
CASI PHARMACEUTICALS : HC Wainwright Adjusts CASI Pharmaceuticals PT to $4 From $3.50, Maintains Buy Rating	21-05-14	MT
CASI PHARMACEUTICALS : Mizuho Security Initiates Coverage on CASI Pharmaceuticals With Buy Rating, $3.80 Price Target	21-04-26	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Secure my Investments

fermer